The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Advair Hfa
fluticasone propionate and salmeterol xinafoate · FLUTICASONE PROPIONATE 115 ug/1; SALMETEROL XINAFOATE 21 ug/1 · Aerosol, Metered · Respiratory (Inhalation) · A-S Medication Solutions
NDC 50090-4504-00 · 1 INHALER in 1 CARTON / 120 AEROSOL, METERED in 1 INHALER · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00173-0716-20) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$25.35per unit
middle half $24.81–$25.57 · 3,661 plans · Apr 1, 2026
Est. net of rebatesⓘ
$15.21–$19.01
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
67%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 95%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for fluticasone propionate and salmeterol xinafoate (other) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- A-S Medication Solutions LLCUnited Statesrelabel
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- NDA021254
- TE code
- —
- Approval date
- Jun 8, 2006
- Patents / exclusivity
- None on file
Shortage history
- Planned discontinuation — Advair HFA, Aerosol, Metered, 115 ug; 21 ug (NDC 0173-0716-22)Jul 27, 2026
- Planned discontinuation — Advair HFA, Aerosol, Metered, 230 ug; 21 ug (NDC 0173-0717-22)Jul 27, 2026
- Planned discontinuation — Advair HFA, Aerosol, Metered, 45 ug; 21 ug (NDC 0173-0715-22)Jul 27, 2026
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of fluticasone propionate and salmeterol xinafoate (Aerosol, Metered)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| GlaxoSmithKline LLC | FLUTICASONE PROPIONATE 230 ug/1; SALMETEROL XINAFOATE 21 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| GlaxoSmithKline LLC | FLUTICASONE PROPIONATE 115 ug/1; SALMETEROL XINAFOATE 21 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| GlaxoSmithKline LLC | FLUTICASONE PROPIONATE 45 ug/1; SALMETEROL XINAFOATE 21 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| Prasco Laboratories | FLUTICASONE PROPIONATE 230 ug/1; SALMETEROL XINAFOATE 21 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| Prasco Laboratories | FLUTICASONE PROPIONATE 45 ug/1; SALMETEROL XINAFOATE 21 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| Prasco Laboratories | FLUTICASONE PROPIONATE 115 ug/1; SALMETEROL XINAFOATE 21 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| A-S Medication Solutions | FLUTICASONE PROPIONATE 115 ug/1; SALMETEROL XINAFOATE 21 ug/1 | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Advair Hfa — NDC 50090-4504-00," retrieved September 3, 2026, https://drugdashboards.com/drug/50090450400.
Free to cite with attribution — see how the data is put together.